Metastatic non-small cell lung cancer without driver mutations: projections by therapy line in Western Europe, 2021–2026 - supplementary material

Supplementary Table 1. Available data in country-specific cancer registries.Supplementary Table 2. Driver mutation literature review.Supplementary Table 3. Projected incidence of non-squamous (A) and squamous (B) non-small cell lung cancer in five Western European countries 2021–2026.Supplementary Table 4. Estimated time to progression by line of therapy for non-squamous and squamous non-small cell lung cancer with no known driver mutations.Supplementary Table 5. Projected number of patients with non-squamous (A) and squamous (B) non-small cell lung cancer with no known driver mutations initiating line of therapy by country and programmed death-ligand 1 status.Supplementary Table 6. First-line maintenance regimens according to the first-line induction systemic therapy regimen used in Stage IIIB/C and IV non-squamous (A) and squamous (B) non-small cell lung cancer patients with no known driver mutations, Western Europe, 2020.<br>